Post-Authorization Safety Surveillance Study of Asenapine in Participants With Bipolar Disorder (P08307)

An Observational Post-Authorization Safety Surveillance (PASS) Study of Sycrest® (Asenapine) Among Patients Aged 18 and Older Diagnosed With Bipolar Disorder

This study will assess asenapine (Sycrest®) use in participants with bipolar disorder; comparison will be made to the use of risperidone (RISPERDAL®CONSTA®) and olanzapine (Zyprexa®). The occurrence of identified and potential clinically important risks will also be assessed.

Inclusion Criteria for the Bipolar Disease Cohort:

• A diagnosis of Bipolar Disorder

Exclusion Criteria for the Bipolar Disease Cohort:

• None

Inclusion Criteria for the potential Schizophrenia Cohort:

• A diagnosis of schizophrenia

Exclusion Criteria for the potential Schizophrenia Cohort:

• A prior and/or concomitant diagnosis of bipolar disease